Medline Inc. IPO - What You Need to Know

Thinking about buying into the Medline IPO? It is a massive name in the medical world. Before you invest your hard-earned money, let’s break down the details from their official filing in plain English.

1. What are you actually buying?

Think of Medline as the "Amazon of hospitals." If you have been in a hospital room, Medline likely supplied the gloves, gowns, bandages, and surgical kits. They are the largest private medical manufacturer and distributor in the U.S., operating a massive network of over 50 distribution centers.

The update: Medline is joining the Nasdaq under the ticker “MDLN.” They are offering 75 million shares to the public.

2. Who gets your money?

Here is a vital detail: Medline does not receive the cash from this IPO.

This is a "secondary offering." The current owners—the Mills family and firms like Blackstone, Carlyle, and Hellman & Friedman—are selling their shares. You are buying ownership from these existing investors. You are not providing new cash to help the company build warehouses or pay down debt.

3. The "UP-C" structure and the tax bill

Medline uses a complex setup called an "UP-C" structure. The original owners keep their ownership in a partnership, while you buy shares in a corporation that sits on top of that partnership.

Why does this matter? It includes a "Tax Receivable Agreement." Medline agreed to pay the original owners 90% of the cash savings they get from specific tax benefits. The company estimates they could owe these owners over $12 billion over the next 15 years. This is a massive future bill that must be paid out of profits, which could leave less money for dividends or reinvestment.

4. How do they make money?

Medline uses a "flywheel" model. They act as a "Prime Vendor," meaning hospitals sign long-term deals to buy almost all their supplies from Medline.

• The Flywheel: By being the main supplier, Medline learns exactly what hospitals need. This helps them sell more of their own "Medline Brand" products, which offer higher profit margins than the items they distribute for others.
• The Growth Engine: They have a major opportunity to convert customers. They currently sell $5 billion worth of third-party products. If they convince hospitals to switch to Medline-branded versions, they estimate it could add $1.3 billion in extra profit.
• Financial Performance: The company generates significant scale, reporting annual revenues exceeding $20 billion and reaching over 100,000 healthcare facilities globally.

5. What are the main risks?

• The "Selling Stockholder" Factor: The current owners are cashing out 75 million shares. This exit by private equity firms often signals that the company is moving from a high-growth phase to a more mature, slower phase.
• The Tax Burden: The Tax Receivable Agreement creates a huge long-term debt. This could limit the company’s cash flow for years, potentially hurting their ability to fund operations or buy other companies.
• Control: The Mills family and private equity partners will keep significant control through a multi-class share structure. As a new investor, your vote on company decisions will carry very little weight.

6. What about the price?

The filing mentions a reference price of $48.89 per share as of late February 2026. However, the actual price you pay will be determined when the stock officially starts trading.

7. The Bottom Line

Medline is a stable, proven business. However, you aren't funding the company's future growth directly; you are buying a piece of the existing pie from current owners. While the business is reliable, be aware of the complex tax agreements that will siphon off future cash to pay the original owners. You are essentially a minority passenger in a car driven by the founding family and private equity firms.

Disclaimer: I am an AI, not a financial advisor. IPOs are often volatile. Never invest money you cannot afford to lose, and always read the company’s official "S-1" filing on the SEC website before making a move.